BJPsych Open
June 1, 2021
Amber Elyse Corrigan, Ella Burchill, Lucy Pelton et al.
1 citation
Aims Depression is the single largest contributor to global disability. However, effective treatments are currently lacking, resulting in a significant burden of treatment-resistant depression (TRD). Psilocybin, a serotonergic psychedelic, found as the active compound in 'magic mushrooms', has been proposed as a novel therapeutic avenue for TRD. We aimed to evaluate the future feasibility and...
Research Square
May 20, 2021
Richard E. Daws, Christopher Timmerman, Bruna Giribaldi et al.
11 citations
preprint
Abstract Importance Psilocybin therapy shows antidepressant potential; our data link its antidepressant effects to decreased brain network modularity post-treatment. Objective To assess the sub-acute impact of psilocybin on brain activity in patients with depression. Design Pre vs post-treatment resting-state functional MRI (fMRI) was recorded in two trials: 1) Open-label treatment-resistant...
Brazilian Journal of Health Review
May 3, 2021
Fabiana Venancio Santana Silva, Alexandre Libanio Silva Reis, Amanda Prazeres Costa et al.
Dados da Organização Mundial de Saúde (OMS) informam que a depressão circunda entre as doenças mais incapacitantes do mundo, estimando-se que mais de 300 milhões de pessoas sofram com esta patologia. A psilocibina é um princípio ativo extraído do cogumelo do gênero Psilocybe de natureza química semelhante ao neurotransmissor serotonina (5- hidroxitriptamina) e a sua ação fisiológica em humanos...
Electronic Journal of General Medicine
April 27, 2021
Hisham Alshaikhli, Redhwan Ahmed Al-Naggar, Gwen Erlam
14 citations
Introduction: Psilocybin mushroom use is well documented in spiritual and religious ceremonies globally. This drug is now the most popular in Europe and the USA. \nObjective: The objective of this study is to explore the experiences and effects of psilocybin on patients with depression and anxiety. \nMethod: A qualitative study was conducted interviewing ten participants currently taking...
April 26, 2021
In patients with major depression, psilocybin was superior to a delayed-treatment control group with an effect size over 2 (relative effect sizes: 0.2 small, 0.5 medium, 1.0 large; antidepressants, on average, are 0.3). Who were these patients? Are they like yours?
Brazilian Journal of Health Review
April 19, 2021
Giovanni Pereira Pio, Aline Moreira Vitorino, Naira Braga Aidar et al.
2 citations
Introdução: A depressão é um transtorno psiquiátrico caracterizado por episódios agudos ou recorrentes de humor deprimido e perda de interesse ou prazer, levando a prejuízos funcionais ao paciente. A psilocibina é uma droga psicodélica com propriedades alucinógenas e serotoninérgicas derivada de cogumelos do gênero Psilocybe. Estudos recentes demonstram potenciais efeitos terapêuticos dessa...
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
April 15, 2021
Dave Nichols
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a...
New England Journal of Medicine
April 14, 2021
Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts et al.
1,372 citations
On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are...
medRxiv
April 7, 2021
David E. Gard, Mollie Pleet, Ellen Bradley et al.
preprint
Abstract Objective: Given the treatment limitations of depression in bipolar disorder, we evaluated the known risks of using psilocybin (and similar substances) in this population, including a systematic assessment of published case histories, to assess the risk of psilocybin as a treatment of depression in bipolar disorder. Data Sources: A comprehensive search of case studies published through...
European Psychiatry
April 1, 2021
A. Fraga, Daniel Esteves-Sousa, João Facucho-Oliveira et al.
1 citation
Introduction Major depressive disorder is a highly prevalent clinical condition, affecting more than 300 million individuals worldwide. About 1/3 of patients with MDD fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression (TRD). Novel antidepressants with rapid and sustained effects on mood and cognition could...